Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2002
05/07/2002US6384192 Amino acid sequence of hedgehog proteins which binds to patched receptor
05/07/2002US6384191 Receptors for fibroblast growth factors
05/07/2002US6384189 Compositions for stimulating TGF-β activity
05/07/2002US6384188 Lipopolysaccharide-binding and neutralizing peptides
05/07/2002US6384187 Administering microsclerodermin or salt to mammal as anticarcinogenic and antitumor agent
05/07/2002US6384186 Cyclic dodecapeptide and process for the preparation thereof
05/07/2002US6384090 Preparation of active ingredient dispersions and apparatus therefor
05/07/2002US6384076 Inhibition or erythrocyte sickling by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester
05/07/2002US6384065 Spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and AP-1 inhibitors containing the same
05/07/2002US6384022 Enzyme inhibitors
05/07/2002US6384017 Methods for treating sex hormone-dependent conditions with Lhrh antagonists
05/07/2002US6384016 One peptide selected from glucagon, glp-1, and analogues and derivatives thereof together with a stabilizing and solubilizing amount of at least one detergent, said detergent having at least 2 positive charges, at least 2 negative
05/07/2002US6384015 Selective lysis of malaria infected erythrocytes
05/07/2002US6384014 Antibiotics as bactericides
05/07/2002US6384013 Cyclic peptide antifungal agents and process for preparation thereof
05/07/2002US6384012 Use of isolated domains of type IV collagen to modify cell and tissue interactions
05/07/2002US6383809 Antisense inhibition of cytohesin-1 expression
05/07/2002US6383808 Antisense inhibition of clusterin expression
05/07/2002US6383807 Method of transforming T lymphocytes
05/07/2002US6383796 Nucleic acids encoding HSKIF21B, a kinesin motor protein
05/07/2002US6383793 Human osteoclast-derived cathepsin
05/07/2002US6383788 Minimizing thermally induced aggregation of DNase in solution with calcium
05/07/2002US6383785 Self-enhancing, pharmacologically controllable expression systems
05/07/2002US6383782 Amino acid sequences of monocyte chemoattractant protein-1; antiinflammatory agents; treatment of rheumatoid arthritis, multiple sclerosis and atherosclerosis
05/07/2002US6383780 2786, a novel human aminopeptidase
05/07/2002US6383779 Glycoprotein VI and uses thereof
05/07/2002US6383768 Method for producing in vitro the RNA-dependent RNA polymerase and terminal nucleotidyl transferase activities encoded by hepatitis C virus (HCV)
05/07/2002US6383761 Methods and compositions for identifying modulators of G-protein-coupled receptors
05/07/2002US6383760 Contacting receptor with test compound, then determining if compound binds to receptor
05/07/2002US6383754 Incubating nucleic acid with cleaving reagents, mixing with offset adaptors that couple with nucleic acid fragments, incubating nucleic acids with cleaving reagents that create sticky ends, mixing and coupling adaptor-indexers to fragments
05/07/2002US6383744 Human checkpoint kinase
05/07/2002US6383739 Drug screening by isolating blood cells then cd8+ cells from donors, culturing with compound for 3 days, culturing in with interleukin-2, detecting immunodeficiency-virus suppressing lymphokine expression, then further analysis
05/07/2002US6383738 Herpes simplex virus ORF P is a repressor of viral protein synthesis
05/07/2002US6383737 Consisting of a polynucleotide encoding the polypeptide comprising amino acid 1 to 578 of a specific amino acid sequence, a polynucleotide capable of hybridizing to above polynuceotide and a fragment of both polynucleotides
05/07/2002US6383733 Methods of screening for pharmacologically active compounds for the treatment of tumour diseases
05/07/2002US6383509 Continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years; neurotoxin, especially botulinum toxin or clostridial neurotoxin, within a polymeric matrix
05/07/2002US6383498 Neuraminidase and galactose oxidase as vaccine adjuvant
05/07/2002US6383496 Recombinant vaccines comprising immunogenic attenuated bacteria having RPOS positive phenotype
05/07/2002US6383494 Heat shock proteins
05/07/2002US6383493 Methods and compositions for eliciting an immune response with hsp70-peptide complexes
05/07/2002US6383492 Treatment of infectious diseases with gp96-peptide complexes
05/07/2002US6383491 Prevention of infectious diseases with hsp90-peptide complexes
05/07/2002US6383488 Pre-M/M epitopes of dengue virus, synthetic peptides, chimeric proteins and their use
05/07/2002US6383487 Antitumor
05/07/2002US6383486 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
05/07/2002US6383485 Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
05/07/2002US6383483 Anticoagulants
05/07/2002US6383480 Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells
05/07/2002US6383479 Neutrophil-activating factor
05/07/2002US6383478 Polymeric encapsulation system promoting angiogenesis
05/07/2002US6383069 Methods and apparatus for performing processing operations on a slaughtered animal or part thereof
05/07/2002CA2361071A1 Combination therapies for the stimulation of bone growth
05/07/2002CA2175842C Transesterified corn oil products
05/07/2002CA1341357C Platelet-specific chimeric immunoglobulin
05/06/2002WO2002038178A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer
05/06/2002CA2429404A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer
05/03/2002WO2002035962A1 Hair clip
05/03/2002CA2377219A1 Hair clip
05/02/2002WO2002035240A2 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors
05/02/2002WO2002035235A2 Net as regulator of angiogenic expression
05/02/2002WO2002034934A2 Stresscopins and their uses
05/02/2002WO2002034933A2 Methods and compositions for modifying biologically active target molecules
05/02/2002WO2002034915A2 Preferred segments of neural thread protein and methods of using the same
05/02/2002WO2002034913A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
05/02/2002WO2002034912A1 Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
05/02/2002WO2002034910A2 Method for modulating granzyme b uptake and for identifying modulators thereof
05/02/2002WO2002034904A1 Novel g protein-coupled receptor protein and dna thereof
05/02/2002WO2002034900A1 Dipeptidyl peptidases
05/02/2002WO2002034899A2 Tec kinase assay
05/02/2002WO2002034896A2 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
05/02/2002WO2002034895A2 Novel aggrecanase molecules
05/02/2002WO2002034887A2 Maturation of dendritic cells
05/02/2002WO2002034885A1 Sericin-containing material, process for producing the same and method of using the same
05/02/2002WO2002034878A2 Amyloid precursor protein and app-derived peptides inhibit tumor growth and metastasis
05/02/2002WO2002034791A2 Methods of purification and recovery of interferon-beta
05/02/2002WO2002034786A1 Method of eliminating human serum albumin polymers
05/02/2002WO2002034783A2 Transmembrane proteins
05/02/2002WO2002034782A2 Endozepine-like polypeptide nov1 and nucleic acid encoding the same
05/02/2002WO2002034781A1 Human g-protein coupled diadenosine tetraphosphate receptor (ap4ar)
05/02/2002WO2002034779A1 Identification and modification of immunodominant epitopes in polypeptides
05/02/2002WO2002034777A1 Fusion proteins as immunization treatments of alzheimer's disease
05/02/2002WO2002034776A2 Epitopes of pai-1
05/02/2002WO2002034773A2 Streptococcal genes
05/02/2002WO2002034770A1 Identification of hla-dr restricted hcv epitopes
05/02/2002WO2002034767A1 Vegf peptides and their use for inhibiting angiogenesis
05/02/2002WO2002034766A2 Peptides derived from the human amyloid precursor protein used to protect cells from iron catalyzed oxidative damage
05/02/2002WO2002034763A2 Mucin comprising vehicle for the transport of biologically-active agents
05/02/2002WO2002034705A2 C-nitroso compounds and use thereof
05/02/2002WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency
05/02/2002WO2002034296A1 A novel gene therapy agent for haemophilia b and its preparation method
05/02/2002WO2002034289A1 Modulating angiogenesis
05/02/2002WO2002034286A1 Methods for treating endocrine disorders
05/02/2002WO2002034285A2 Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
05/02/2002WO2002034284A2 Methods of therapy for hiv infection
05/02/2002WO2002034283A2 Vegh inhibitors and their use
05/02/2002WO2002034282A2 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
05/02/2002WO2002034281A1 Method for promoting hair growth
05/02/2002WO2002034280A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain
05/02/2002WO2002034272A2 Methods of improving central nervous system functioning
05/02/2002WO2002034248A2 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION